Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CTLA4Ig: bridging the basic immunology with clinical application.

Jeffrey A Bluestone1, E William St Clair, Laurence A Turka

  • 1Diabetes Center, University of California, San Francisco, San Francisco, California 94143, USA. jbluest@immunetolerance.org

Immunity
|March 21, 2006
PubMed
Summary

The FDA approved CTLA4Ig (cytotoxic T-lymphocyte-associated protein 4-immunoglobulin) in 2005 for rheumatoid arthritis. This drug, Orencia, targets CD28 costimulation, marking a significant advancement in treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacology and nonclinical development of teplizumab, a first-in-class immunotherapy for delaying the onset of type 1 diabetes.

The Journal of pharmacology and experimental therapeutics·2026
Same author

Revisiting the CD40-CD40L axis: from mechanistic insight to therapeutic renewal in autoimmune disease.

Current opinion in rheumatology·2026
Same author

Gene-corrected regulatory T cell therapy for IL2RA deficiency.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

The 2025 Nobel Prize in Physiology or Medicine - a bridge to peripheral immune tolerance.

The Journal of clinical investigation·2025
Same author

Plain language summary: treatment of Sjögren's disease with dazodalibep.

Immunotherapy·2025
Same author

Receptor-tethered orthogonal IL-2 enhances regulatory T cell therapy.

bioRxiv : the preprint server for biology·2025

Area of Science:

  • Immunology
  • Rheumatology
  • Drug Development

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease.
  • CD28 costimulation plays a crucial role in T-cell activation and immune responses.
  • Developing targeted therapies for RA has been a long-standing challenge.

Purpose of the Study:

  • To discuss the scientific rationale behind the development of CTLA4Ig.
  • To review the clinical challenges encountered in bringing CTLA4Ig (Orencia) to patients.
  • To highlight the significance of Orencia as a first-in-class CD28 costimulation antagonist.

Main Methods:

  • Review of preclinical research and scientific literature.
  • Analysis of clinical trial data and regulatory pathways.

Related Experiment Videos

  • Discussion of the translation from basic science to clinical application.

    • Main Results:

    • CTLA4Ig (Orencia) was approved by the FDA in December 2005 for rheumatoid arthritis treatment.
    • Orencia represents a novel therapeutic approach by antagonizing CD28 costimulation.
    • The development pathway involved overcoming significant scientific and clinical hurdles.

    Conclusions:

    • The journey to FDA approval for CTLA4Ig was complex, involving extensive research and development.
    • Orencia's approval signifies a major milestone in the treatment of rheumatoid arthritis.
    • Understanding the science and challenges of drug development is crucial for future therapeutic innovations.